[go: up one dir, main page]

HK1032538A1 - Pharmaceutical formulation of a didemnin compound - Google Patents

Pharmaceutical formulation of a didemnin compound

Info

Publication number
HK1032538A1
HK1032538A1 HK01103194A HK01103194A HK1032538A1 HK 1032538 A1 HK1032538 A1 HK 1032538A1 HK 01103194 A HK01103194 A HK 01103194A HK 01103194 A HK01103194 A HK 01103194A HK 1032538 A1 HK1032538 A1 HK 1032538A1
Authority
HK
Hong Kong
Prior art keywords
didemnin
pharmaceutical formulation
compound
didemnin compound
lyophilized
Prior art date
Application number
HK01103194A
Other languages
English (en)
Inventor
Jacob Hendrik Beijnen
Bastiaan Nuyen
Roland E C Henrar
Andres Gomez
Jose Jimeno
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10827213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1032538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of HK1032538A1 publication Critical patent/HK1032538A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01103194A 1998-02-18 2001-05-07 Pharmaceutical formulation of a didemnin compound HK1032538A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803448.1A GB9803448D0 (en) 1998-02-18 1998-02-18 Pharmaceutical formulation
PCT/GB1999/000511 WO1999042125A1 (en) 1998-02-18 1999-02-18 Pharmaceutical formulation of a didemnin compound

Publications (1)

Publication Number Publication Date
HK1032538A1 true HK1032538A1 (en) 2001-07-27

Family

ID=10827213

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01103194A HK1032538A1 (en) 1998-02-18 2001-05-07 Pharmaceutical formulation of a didemnin compound

Country Status (17)

Country Link
US (1) US8420130B1 (pt)
EP (1) EP1054686B1 (pt)
JP (2) JP4536255B2 (pt)
KR (1) KR100595597B1 (pt)
CN (1) CN1170586C (pt)
AT (1) ATE217532T1 (pt)
AU (1) AU754073B2 (pt)
BR (1) BRPI9908088C1 (pt)
CA (1) CA2321116C (pt)
DE (1) DE69901487T2 (pt)
DK (1) DK1054686T3 (pt)
ES (1) ES2175940T3 (pt)
GB (1) GB9803448D0 (pt)
HK (1) HK1032538A1 (pt)
IL (1) IL137911A (pt)
PT (1) PT1054686E (pt)
WO (1) WO1999042125A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
DE10008128A1 (de) * 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
RU2003113210A (ru) 2000-10-12 2004-11-27 Фарма Мар, С.А. (Es) Лечение раковых заболеваний
ATE314084T1 (de) * 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
JP2006519848A (ja) 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
RU2335294C2 (ru) * 2003-03-12 2008-10-10 Дана-Фарбер Кэнсер Инститьют, Инк. Аплидин для лечения множественной миеломы
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN100335495C (zh) * 2006-01-23 2007-09-05 南方医科大学 一种海鞘多肽及其制备方法
KR20140101014A (ko) 2006-02-28 2014-08-18 파르마 마르 에스.에이. 개선된 항종양 치료
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US10286037B2 (en) 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR20220150348A (ko) 2020-03-02 2022-11-10 파르마 마르, 에스.에이. 코로나바이러스의 치료에 조합하여 사용하기 위한 pld
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
CN115666615A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于治疗冠状病毒感染的化合物
PE20230412A1 (es) 2020-03-02 2023-03-07 Pharma Mar Sa Compuestos para su uso en afecciones inflamatorias
CN114085272B (zh) * 2022-01-10 2022-06-10 中山大学 一种isaridin类环酯肽衍生物及其制备方法和应用
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
JPS5781413A (en) * 1980-09-12 1982-05-21 Univ Illinois Didemnin antibiotic
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ATE220894T1 (de) * 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
ATE196844T1 (de) 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
DE69708114T2 (de) 1996-07-03 2002-07-04 C. G. Paxton Ltd., Walsall Behälter
CA2269881A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
AU726146B2 (en) 1996-10-24 2000-11-02 Board Of Trustees Of The University Of Illinois, The Total synthesis of the amino hip analogue of didemnin A
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
JP4327260B2 (ja) * 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ES2235499T3 (es) 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003500360A (ja) 1999-05-25 2003-01-07 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物類を含む抗癌剤
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003514025A (ja) 1999-11-15 2003-04-15 ファルマ・マール・ソシエダード・アノニマ ガンのアプリジン治療
NZ521844A (en) 2000-04-07 2004-07-30 Univ Pennsylvania Tamandarin and didemnin analogs having deoxo-proline residue or dehydro-proline residue and methods of making and use thereof
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA03002479A (es) 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
DE60111858T2 (de) 2000-10-12 2006-04-20 Pharma Mar, S.A., Tres Cantos BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
CA2462642A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
JP2006519848A (ja) 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療

Also Published As

Publication number Publication date
JP2010163443A (ja) 2010-07-29
KR100595597B1 (ko) 2006-07-03
DE69901487T2 (de) 2002-12-19
IL137911A0 (en) 2001-10-31
CA2321116C (en) 2009-10-06
KR20010040993A (ko) 2001-05-15
GB9803448D0 (en) 1998-04-15
JP4536255B2 (ja) 2010-09-01
BRPI9908088B8 (pt) 2017-03-07
CN1330551A (zh) 2002-01-09
ES2175940T3 (es) 2002-11-16
BR9908088B1 (pt) 2013-05-21
CA2321116A1 (en) 1999-08-26
PT1054686E (pt) 2002-09-30
ATE217532T1 (de) 2002-06-15
US8420130B1 (en) 2013-04-16
AU2538999A (en) 1999-09-06
EP1054686B1 (en) 2002-05-15
IL137911A (en) 2006-04-10
BR9908088A (pt) 2000-10-31
EP1054686A1 (en) 2000-11-29
DK1054686T3 (da) 2002-06-17
WO1999042125A1 (en) 1999-08-26
BRPI9908088C1 (pt) 2021-05-25
DE69901487D1 (de) 2002-06-20
CN1170586C (zh) 2004-10-13
AU754073B2 (en) 2002-11-07
JP2002503704A (ja) 2002-02-05

Similar Documents

Publication Publication Date Title
HK1032538A1 (en) Pharmaceutical formulation of a didemnin compound
EP1093819A3 (en) Compounds and compositions for delivering active agents
IL140710A0 (en) Pulmonary delivery of active agents
CA2126091A1 (fr) Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
HUP0002126A3 (en) Non-steroidal (hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity, process for their preparation and pharmaceutical compositions thereof
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
MX9502034A (es) Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion.
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
SI0984982T1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them
YU23302A (sh) Farmaceutski preparati fibrinolitičkog agensa
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
HUP0101098A3 (en) Streptogramin derivatives, process for preparation thereof and compositions containing same
PL345811A1 (en) Pharmaceutical compositions comprising ibuprofen and domperidone
IL120590A (en) N-(2-hydroxy-1-phenylethyl)pyrimido¬1,2-a¾indol-10-ylmethylphenyl-acetamides their preparation and pharmaceutical compositions containing them
IL121969A0 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives their preparation and pharmaceutical compositions containing them
AU3953197A (en) Catechol amino acid derivatives and pharmaceutical compositions containing them
HUP0200481A2 (en) Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines, process for their preparation and pharmaceutical compositions containing them
PL333358A1 (en) Conformingly stable lh-rh analogues, their application and compositions containing them
IL96216A0 (en) Peptide derivatives,their preparation and pharmaceutical compositions containing them
AU2513899A (en) Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
AU5993198A (en) Novel mixed benzene acid derivatives, method for preparing them and pharmaceutical compositions containing same
GB9718415D0 (en) Formulation
IL98478A0 (en) Hybrid fibrinolytic enzyme,its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20190217